medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 6

<< Back Next >>

Ann Hepatol 2017; 16 (6)

Hepatitis C and Its Metabolic Complications in Kidney Disease

Fabrizi F, Donato FM, Messa P

Language: English
References: 66
Page: 851-861
PDF size: 217.27 Kb.


ABSTRACT

Introduction. Evidence has been accumulated during the last decade showing that HCV infection plays an important activity at hepatic and extra-hepatic level. Chronic HCV is associated with a large spectrum of extra-hepatic manifestations including lympho-proliferative diseases and metabolic abnormalities (such as insulin resistance and fatty liver disease). Material and methods. We have performed an extensive review of the medical literature regarding the increased risk of cardiovascular and kidney disease that has been observed in various groups of HCV-infected patients. The potential link between such increased risk and the metabolic consequences of chronic HCV infection has been explored. Results. According to a systematic review with a meta-analysis of longitudinal studies (n = 9 clinical observational studies; n = 1,947,034 unique patients), we found a strong relationship between positive anti-HCV serologic status and increased incidence of chronic kidney disease in the adult general population, the summary estimate for adjusted hazard ratio was 1.43 (95% confidence intervals, 1.23; 1.63, P = 0.0001) (random-effects model) in anti-HCV positive patients. In another meta-analysis of clinical observational studies (n = 145,608 unique patients on long term dialysis; n = 14 observational studies), anti-HCV sero-positive status was an independent and significant risk factor for death in patients on maintenance dialysis. The summary estimate for adjusted relative risk (all-cause mortality) was 1.35 with a 95% confidence interval (CI) of 1.25; 1.47 (P ‹ 0.01) in anti-HCV positive patients on maintenance dialysis. An updated and stratified analysis (n = 4 studies, n = 91,916 patients on maintenance dialysis) resulted in an adjusted HR for cardiovascular mortality among anti-HCV positive patients of 1.21 (95% CI, 1.06; 1.39) (P ‹ 0.01); the homogeneity assumption was not rejected. The mechanisms underlying such relationships remain unclear; it has been suggested that HCV promotes atherogenesis through direct and indirect mechanisms. Conclusions. Clinical trials are under way to assess whether the clearance of HCV RNA from serum by direct-acting antiviral drugs reduces allcause or disease-specific (cardiovascular) mortality among patients on maintenance dialysis.


REFERENCES

  1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73(Suppl. 109): S1-S99.

  2. CDC. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR 2001; 5: 1-43.

  3. Fissell R, Bragg-Gresham J, Woods J, Jadoul M, Gillespie B, Hedderwick S, Rayner H, et al. Patterns of hepatitis C prevalence and seroconversion on haemodialysis from three continents: the DOPPS. Kidney Int 2004; 65: 2335-42.

  4. Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M. Hepatitis C infection is very rarely treated among haemodialysis patients. Am J Nephrol2013; 38(5): 405-12.

  5. Alashek W, McIntyre C, Taal W. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 2012; 12: 265.

  6. Su Y, Yan R, Duan Z, Norris J, Wang L, Jiang Y, Xing W, et al. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: a multicenter study in Beijing, China. J Med Virol 2013; 85: 425-32.

  7. Unmate I, Denue B, Kida I, Ohioma O, Baba D, Goni W. Risk factors for hepatitis C virus seropositivity among hemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med J 2014; 19: 305.

  8. Zahran A. Prevalence of seroconversion of hepatitis C virus among hemodialysis patients in Menoufia Governorate, Egypt. Arab J Nephrol Transplant 2014; 7: 133-5.

  9. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, et al. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 2014; 25: 672-9.

  10. Dumaidi K, Al-Jawabreh A. Prevalence of occult HBV among haemodialysis patients in two districts in the northern part of the West Bank, Palestine. J Med Virol 2014; 86: 1694-9.

  11. Schiller A, Timar R, Siriopol D, Timar B, Bob F, Schiller O, Drug V, et al. Hepatitis B and C virus infection in the hemodialysis population from three Romanian regions. Nephron 2015; 129: 202-8.

  12. Duong C, Olszyna D, McLaws M. Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health 2015; 15: 192.

  13. Vidales-Braz B, da Silva N, Lobato R, Germano F, da Mota L, Barros E, de Martinez A. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in haemodialysis patients. J Virol 2015; 12: 8. Doi: 10.1186/s12985-015-0238-z.

  14. Aman K, Al-Dubai S, Aman R, Hawash A, Alshagga M, Kassim S. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialuysis in three health centers in Aden, Yemen: a cross-sectional study. Saudi J Kidney Dis Transpl 2015; 26: 380-5.

  15. Malhotra R, Soin D, Grover P, Galhotra S, Khutan H, Kaur N. Hepatitis B virus and hepatitis C virus co-infection in haemodialysis patients: A retrospective study from a tertiary care hospital of North India. J Nat Sci Biol Med 2016; 7: 72-4.

  16. Halle M, Choukem S, Kaze F, Ashuntantang G, Tchamago V, Mbour-Djieka Y, Temfack E, et al. Hepatitis B, hepatitis C, and human immunodeficiency virus seroconversion positivity rates and their potential risk factors among patients on maintenance haemodialysis in Cameroon. Iran J Kidney Dis 2016; 10: 304-9.

  17. Hasanjani Roushan M, Farokhtabar S, Bayani M, Siadati S. Epidemiological aspects of hepatitis B and C and human immunodeficiency viruses among haemodialysis patients in Mazandaran Province, Iran. Nephrourol Mon 2016; 8: e37878.

  18. Locatelli F, de Francisco A, Deray G, Fliser D, Armstrong G, Dougherty F, Ehrhard P. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract 2014; 128: 323-32.

  19. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality ? J Viral Hepat 2012; 19: 601-7.

  20. Kalantar-Zadeh K, McAllister C, Miller L. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-9.

  21. Scott D, Wong J, Spicer T, Dent H, Mensah F, McDonald S, Levy M. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-71.

  22. Ohsawa M, Kato K, Tanno K, Itai K, Fujishima Y, Okayama A, Turin T, et al. Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver-disease-related mortality in haemodialysis patients. J Epidemiology 2011; 21: 491-9.

  23. Goodkin D, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni R. Mortality, Epidemiology, hospitalization, and quality of life among haemodialysis patients with hepatitis C infection. Clin J Am Soc Nephrol 2017; 12: 287-9.

  24. Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5: 528-40.

  25. Adinolfi L, Zampino R, Restivo R, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-7.

  26. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int 2013; 7 (Suppl. 2): S782-S789.

  27. Voulgaris T, Sevastianos V. Atherosclerosis as extra-hepatic manifestation of chronic infection with hepatitis C virus. Hep Res Treatment 2016; 7629318.

  28. Ampuero J, Romero-Gomez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol 2015; 8: 2214-29.

  29. Petta S, Maida M, Macaluso F, Barbara M, Licata A, Craxi A, Cammà C. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 2016; 150: 145-55.

  30. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: A systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.

  31. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int 2005; 67: 285-90.

  32. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006; 260: 255-62.

  33. Tsui J, Vittinghoff E, Shlipak M, O’Hare A. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-74.

  34. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008; 38: 775-83.

  35. Yanik E, Lucas G, Vkahov D, Kirk G, Mehta S. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol 2010; 5: 1836-43.

  36. Lee J, Lee M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with chronic kidney disease in an endemic area in Taiwan. A cross-sectional study. Am J Kidney Dis 2010; 56: 23-31.

  37. Kurbanova N, Qayyum R. Association of hepatitis C virus infection with proteinuria and glomerular filtration rate. Clin Transl Sci 2015; 8: 421-4.

  38. Tsui J, Vittinghoff E, Shlipak M, Berthental D, Inadomi J, Rodriguez R, O’Hare A. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167: 1271-6.

  39. Moe S, Pampalone A, Ofner S, Rosenman M, Teal E, Hsiu S. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008; 51: 885-92.

  40. Asrani S, Buchanan P, Pinski B, Rey L, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010; 8: 79-84.

  41. Dalrymple L, Koepsell T, Sampson J, Louie T, Dominitz J, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2007; 2: 715-21.

  42. Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, et al., for the NA-ACCORD of the IeDEA. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208: 1240-9.

  43. Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012; 6: 369-78.

  44. Gilbert A, Lion G. Arterites infectieuses experimentales. C R Hebd Seances Soc Biol Fil 1889; 41 : 583-4.

  45. Stassen F, Vainas T, Bruggeman C. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep 2008; 60: 85-92.

  46. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, Rossi L, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010; 47: 72-5.

  47. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K, Ogawa S, et al. High prevalence and adverse effects of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11: 690-9.

  48. Crook E, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005; 298: 2187-91.

  49. Noureddine L, Usman S, Yu Z, Moorthi R, Moe S. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol 2010; 32: 311-6.

  50. Ble M, Aguilera V, Rubin A, Garcia-Eliz M, Vinaixa C, Prieto M, Berenguer M. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl 2014; 20: 25-34.

  51. Bergman S, Accort N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005; 45: 684-9.

  52. Iwasa Y, Otsubo S, Sugi O, Sato K, Asamiya Y, Eguchi A, Iwasaki T, et al. Patterns in the prevalence of hepatitis C virus infection at the start of haemodialysis in Japan. Clin Exp Nephrol 2008; 12: 53-7.

  53. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen M, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis 2009; 54: 43-50.

  54. Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008; 22: 1799-807.

  55. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J Med Virol 2016; 88: 487-97.

  56. Norton B, Park L, McGrath L, Proeschold Bell R, Muir A, Naggie S. Health care utilization in HIV-infected patients: Assessing the burden of hepatitis C virus co-infection. AIDS Patient Care and STDs 2012; 26: 541-5.

  57. Wang C, Wang S, Yao W, Chang T, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community- based longitudinal study. Am J Epidemiol 2007; 166: 196-203.

  58. Chien C, Lin C, Hu C, Chang J, Chien R. Clearance of hepatitis C virus improves insulin resistance during and after peginterferon and ribavirin therapy. J Interferon Cytokine Res 2015; 35: 981-9.

  59. Musso G, Gambino R, Tabibian J, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, et al. Association of non –alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLOs One 2014; 11: e1001680.

  60. Hsu C, Kao J, Chao Y, Lin H, Fan Y, Huang C, Tsai P. Interferon- based therapy reduces risk of stroke in chronic hepatitis C patients: a population based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-23.

  61. Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, et al.; GESIDA HIV/ HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients co-infected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55: 728-36.

  62. Hsu Y, Ho H, Huang Y, Wang H, Wu M, Lin J, Wu C. Association between antiviral treatment and extra-hepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.

  63. Chen Y, Hwang S, Li C, Wu C, Lin L. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine 2015; 94: e1334.

  64. Hsu Y, Lin J, Ho H, Kao Y, Huang Y, Hsiao N, Wu M, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302.

  65. Arase Y, Suzuki F, Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 2011; 41: 946-54.

  66. Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S, Saracino A, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV –coinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis 2016; 35: 1511-20.




2020     |     www.medigraphic.com